Augmenix at ESTRO 2017
PEG Hydrogel Spacing for Prostate Radiotherapy:
Now with positive 3-year toxicity and QOL data.
What: Augmenix Satellite Lunch Symposium at ESTRO 36
Date: Monday 8 May, 13:15 – 14:15
Location: STOLZ 1-2
Augmenix, Inc will be sponsoring a satellite symposium during ESTRO 36 on 8 May in Vienna to share the latest clinical evidence on the SpaceOAR® System. Used in prostate cancer radiotherapy, SpaceOAR System is an absorbable PEG hydrogel that temporarily moves the rectum away from the prostate and the high radiation zone. The space created significantly reduces the radiation delivered to the rectum while allowing increased dosage to the prostate.
The final results of the SpaceOAR System phase III trial including a three-year post treatment follow-up will be presented by Brian Davis, MD, PhD, Professor of Radiation Oncology, Rochester, Minnesota USA. The study results were recently published in the April 2017 Red Journal. Results demonstrated a significant reduction in late rectal toxicity complications, along with favorable bowel, urinary and sexual QOL measurements.
In addition, Razvan Galalae, MD, PhD, Associate Professor, Christian Albrechts University of Kiel and Head of the Department of Radiotherapy, Evangelical Clinics Gelsenkirchen, Germany will present the use of SpaceOAR Hydrogel in high precision prostate radiotherapy using interstitial adaptive brachytherapy and VMAT.